Kuangli Bio-Tech Holdings Co (TPE:6431) Cyclically Adjusted Revenue per Share: NT$5.73 (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

TPE:6431 Kuangli Bio-Tech Holdings Co Ltd TPE:6431
66 GF Score
Price NT$17.20
GF Value NT$11.63
Valuation Significantly Overvalued
! 7 Warning Signs
View Full Analysis

What is Kuangli Bio-Tech Holdings Co Cyclically Adjusted Revenue per Share?

Kuangli Bio-Tech Holdings Co TPE:6431 -0.86% 66 Cyclically Adjusted Revenue per Share is NT$5.73 as of Dec. 2025. GuruFocus rates TPE:6431 with a GF Score™ of 66/100 and a GF Value™ of NT$11.63 (Significantly Overvalued). The stock has 7 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Kuangli Bio-Tech Holdings Co's adjusted revenue per share for the three months ended in Dec. 2025 was NT$1.170. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is NT$5.73 for the trailing ten years ended in Dec. 2025.

During the past 12 months, Kuangli Bio-Tech Holdings Co's average Cyclically Adjusted Revenue Growth Rate was -10.60% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

As of today (2026-07-26), Kuangli Bio-Tech Holdings Co's current stock price is NT$17.20. Kuangli Bio-Tech Holdings Co's Cyclically Adjusted Revenue per Share for the quarter that ended in Dec. 2025 was NT$5.73. Kuangli Bio-Tech Holdings Co's Cyclically Adjusted PS Ratio of today is 3.00.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Kuangli Bio-Tech Holdings Co was 5.19. The lowest was 1.39. And the median was 2.61.


Kuangli Bio-Tech Holdings Co  (TPE:6431) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Kuangli Bio-Tech Holdings Co's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=17.20/5.73
=3.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Kuangli Bio-Tech Holdings Co was 5.19. The lowest was 1.39. And the median was 2.61.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Kuangli Bio-Tech Holdings Co Cyclically Adjusted Revenue per Share Related Terms


Kuangli Bio-Tech Holdings Co Cyclically Adjusted Revenue per Share Historical Data

* Premium members only.

The historical data trend for Kuangli Bio-Tech Holdings Co's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Kuangli Bio-Tech Holdings Co Cyclically Adjusted Revenue per Share Chart

Kuangli Bio-Tech Holdings Co Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 9.00 6.41 5.73

Kuangli Bio-Tech Holdings Co Quarterly Data
Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 6.41 6.33 6.11 5.92 5.73

TPE:6431 vs PG, CL, KVUE: Cyclically Adjusted Revenue per Share Comparison

For the Household & Personal Products subindustry, Kuangli Bio-Tech Holdings Co's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Kuangli Bio-Tech Holdings Co Cyclically Adjusted PS Ratio vs Consumer Packaged Goods Industry

For the Consumer Packaged Goods industry and Consumer Defensive sector, Kuangli Bio-Tech Holdings Co's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Kuangli Bio-Tech Holdings Co's Cyclically Adjusted PS Ratio falls into.


TPE:6431
66GF Score
Kuangli Bio-Tech Holdings Co Ltd TPE:6431
Cyclically Adjusted Revenue per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Kuangli Bio-Tech Holdings Co Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Kuangli Bio-Tech Holdings Co's adjusted Revenue per Share data for the three months ended in Dec. 2025 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Dec. 2025 (Change)*Current CPI (Dec. 2025)
=1.17/324.0540*324.0540
=1.170

Current CPI (Dec. 2025) = 324.0540.

Kuangli Bio-Tech Holdings Co Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201603 1.348 238.132 1.834
201606 1.176 241.018 1.581
201609 0.903 241.428 1.212
201612 1.181 241.432 1.585
201703 0.741 243.801 0.985
201706 0.646 244.955 0.855
201709 0.442 246.819 0.580
201712 0.502 246.524 0.660
201803 0.448 249.554 0.582
201806 0.616 251.989 0.792
201809 0.701 252.439 0.900
201812 0.493 251.233 0.636
201903 0.670 254.202 0.854
201906 1.231 256.143 1.557
201909 2.559 256.759 3.230
201912 4.846 256.974 6.111
202003 0.790 258.115 0.992
202006 0.876 257.797 1.101
202009 0.807 260.280 1.005
202012 -0.570 260.474 -0.709
202103 0.000 264.877 0.000
202106 1.040 271.696 1.240
202109 2.529 274.310 2.988
202112 2.953 278.802 3.432
202203 1.118 287.504 1.260
202206 1.081 296.311 1.182
202209 2.012 296.808 2.197
202212 1.879 296.797 2.052
202303 0.967 301.836 1.038
202306 1.781 305.109 1.892
202309 1.003 307.789 1.056
202312 1.334 306.746 1.409
202403 1.075 312.332 1.115
202406 1.247 314.175 1.286
202409 1.463 315.301 1.504
202412 1.717 315.605 1.763
202503 1.377 319.799 1.395
202506 0.884 322.561 0.888
202509 0.689 324.800 0.687
202512 1.170 324.054 1.170

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

What does a Cyclically Adjusted Revenue per Share of NT$5.73 mean?
Kuangli Bio-Tech Holdings Co (TPE:6431) has a Cyclically Adjusted Revenue per Share of NT$5.73 as of Dec. 2025. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Kuangli Bio-Tech Holdings Co and its competitors.
Is Kuangli Bio-Tech Holdings Co's Cyclically Adjusted Revenue per Share too high?
Kuangli Bio-Tech Holdings Co's current Cyclically Adjusted Revenue per Share is NT$5.73. Overall, Kuangli Bio-Tech Holdings Co has a GF Score™ of 66/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Kuangli Bio-Tech Holdings Co's Cyclically Adjusted Revenue per Share compare to PG and CL?
Kuangli Bio-Tech Holdings Co's Cyclically Adjusted Revenue per Share of NT$5.73 can be compared against companies in the Consumer Packaged Goods industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Revenue per Share for a Consumer Packaged Goods company?
A good Cyclically Adjusted Revenue per Share depends on the Consumer Packaged Goods industry context. However, Cyclically Adjusted Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Revenue per Share mean?
A high Cyclically Adjusted Revenue per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Kuangli Bio-Tech Holdings Co and its competitors. Kuangli Bio-Tech Holdings Co's current Cyclically Adjusted Revenue per Share is NT$5.73. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Kuangli Bio-Tech Holdings Co stock overvalued right now?
Based on GuruFocus' analysis, Kuangli Bio-Tech Holdings Co (TPE:6431) is currently considered Significantly Overvalued. The stock's GF Value™ is NT$11.63, compared to a current price of NT$17.20 — trading 47.9% above its estimated fair value. The current Cyclically Adjusted Revenue per Share is NT$5.73. Kuangli Bio-Tech Holdings Co's overall GF Score™ is 66/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Revenue per Share calculated?
Cyclically Adjusted Revenue per Share is calculated from a company's financial statements. For Kuangli Bio-Tech Holdings Co (TPE:6431), the current Cyclically Adjusted Revenue per Share is NT$5.73 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Kuangli Bio-Tech Holdings Co (TPE:6431) Overvalued in 2026?

Based on GuruFocus' analysis, Kuangli Bio-Tech Holdings Co stock appears to be overvalued. The current stock price of NT$17.20 is trading 47.9% above its estimated GF Value™ of NT$11.63. GuruFocus considers Kuangli Bio-Tech Holdings Co to be Significantly Overvalued.

Key valuation signals for TPE:6431:

  • Cyclically Adjusted Revenue per Share: NT$5.73
  • GF Value™: NT$11.63 vs. price of NT$17.20 (47.9% above fair value)
  • GF Score™: 66/100 with 7 warning signs

No single metric tells the full story. See the TPE:6431 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Kuangli Bio-Tech Holdings Co Business Description

Address North Sound Road, Suite 102, Cannon Place, George Town, Grand Cayman, CYM
Kuangli Bio-Tech Holdings Co Ltd is mainly engaged in the manufacture and trading of various types of panels (LENS), such as mobile phone panels, digital camera windows, PDA panels, and instrument panels. The company is also engaged in the development, manufacturing and trading of cosmetics and skin care products and other related biotechnology products. It derives revenue from Health and Wellness products, and Cosmetics and skin care products, including Lotion, Facial masks, and Other pastes. The primary source of revenue for the company is sales of cosmetic products.
66GF Score

Get the complete analysis for TPE:6431

Cyclically Adjusted Revenue per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$17.20
Price
NT$11.63
GF Value